Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

Xpert MTB/RIF Ultra for Detection of Mycobacterium tuberculosis in Cerebrospinal Fluid

Jerome H. Chin, Abdu K. Musubire, Nicole Morgan, Jacob Pellinen, Scott Grossman, Jaydeep M. Bhatt, Vincent Wadda, Willy Ssengooba
Melissa B. Miller, Editor
Jerome H. Chin
aDepartment of Neurology, NYU Langone Health, New York, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jerome H. Chin
Abdu K. Musubire
cDepartment of Medicine, Makerere University, Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole Morgan
aDepartment of Neurology, NYU Langone Health, New York, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacob Pellinen
aDepartment of Neurology, NYU Langone Health, New York, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Grossman
aDepartment of Neurology, NYU Langone Health, New York, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaydeep M. Bhatt
aDepartment of Neurology, NYU Langone Health, New York, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Wadda
cDepartment of Medicine, Makerere University, Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Willy Ssengooba
bDepartment of Medical Microbiology, Makerere University, Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa B. Miller
University of North Carolina School of Medicine
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JCM.00249-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

LETTER

Tuberculous meningitis (TBM) is the most lethal manifestation of tuberculosis and requires rapid diagnosis and initiation of treatment to prevent death and serious neurological disability. The Xpert MTB/RIF assay (Xpert) (Cepheid, USA) is a fully automated nucleic acid amplification test that detects the Mycobacterium tuberculosis rpoB gene and associated mutations that confer rifampin resistance. Xpert was approved by the WHO in 2010 for the diagnosis of pulmonary and extrapulmonary tuberculosis (1). The next-generation Xpert MTB/RIF Ultra assay (Xpert Ultra) was approved by the WHO in March 2017 (1). Xpert Ultra includes two additional hybridization targets (IS6110 and IS1081 genes), as well as a larger reaction chamber, all of which boost the analytical sensitivity of Xpert Ultra to almost 8 times higher than that of Xpert (2). A number of studies have demonstrated a higher sensitivity of Xpert Ultra compared to that of Xpert for the detection of M. tuberculosis in pulmonary specimens (3–7). To date, only one study of the performance of Xpert Ultra for detecting M. tuberculosis in cerebrospinal fluid (CSF) has been published (8). The study included CSF samples from 23 HIV-infected patients with probable or definite TBM and reported sensitivities of 70%, 43%, and 43% for Xpert Ultra, Xpert, and mycobacterial culture, respectively.

Xpert Ultra became available at our laboratory in Uganda in October 2017. We have since included Xpert Ultra testing of CSF as part of the routine diagnostic investigation of 11 patients with suspected TBM admitted to the neurology ward of Mulago/Kiruddu National Referral Hospital. Using retrospective routine laboratory data, we present here the CSF results for these 11 patients. All of the patients had computed tomography (CT) imaging of the brain and fulfilled uniform case definition criteria for probable or definite TBM (9). Two patients had HIV infection and were not taking antiretroviral medication. Antituberculosis therapy (ATT) was started on all patients after CSF collection, except that for patient 7, who was started on ATT by the referring hospital 10 days prior to CSF collection. Our laboratory protocol is to apply uncentrifuged and undiluted CSF for Xpert and Xpert Ultra testing as previously described (10). Mycobacterial growth indicator tubes (MGIT) (Bactec MGIT 960; Becton, Dickinson and Company, USA) are inoculated with a CSF volume of 0.8 ml.

All CSF samples showed pleocytosis with lymphocytic predominance and elevated protein levels (>45 mg/dl) (Table 1). Most samples showed reduced glucose levels (<2.2 mmol/liter). Gram stain, Ziehl-Neelsen stain, India ink preparation, and routine bacterial cultures were negative for all samples. Cryptococcal antigen testing was done on CSF samples from patients with positive or unknown HIV 1/2 serology status at the time of lumbar puncture (patients 1, 2, 5, 8, 10, and 11), and all assay results were negative. Xpert Ultra detected M. tuberculosis in 7 of the 11 CSF samples (2 low, 2 very low, and 3 trace). All 4 samples positive by Xpert were positive by Xpert Ultra. Xpert Ultra detected M. tuberculosis in 2 samples that were negative by Xpert and MGIT culture and in 1 sample that was negative by Xpert and positive by MGIT culture. Xpert and Xpert Ultra failed to detect M. tuberculosis in 1 sample that was positive by MGIT culture. Overall, 5 of the 11 CSF samples were positive by MGIT culture. Given that all patients were clinically ill with meningitis, it is unlikely that the two Xpert Ultra-positive/MGIT-negative samples are false positives. Both patients improved on ATT and were discharged to home. Patient 6 was lost to follow-up, and patient 5 is alive on ATT at 6 months. No rifampin resistance was detected by Xpert, Xpert Ultra, or MGIT culture.

View this table:
  • View inline
  • View popup
TABLE 1

CSF results of patients with tuberculous meningitis

Our observations of a higher rate of detection of M. tuberculosis in CSF by Xpert Ultra compared to Xpert and MGIT culture are very similar to the findings of Bahr et al. (8). Notably, the majority of our patients were HIV uninfected. Since we inoculated uncentrifuged CSF, the MGIT culture positivity rate may have been lower than what could have been achieved using the sediment after centrifugation of a large-volume CSF sample. We believe that Xpert Ultra has a very useful role for the rapid detection of M. tuberculosis and rifampin resistance in CSF. However, a trace-positive Xpert Ultra result cannot provide drug resistance information (2). M. tuberculosis cultures should be performed, at a minimum, on Xpert- and Xpert Ultra-negative CSF samples and on Xpert Ultra-trace-positive CSF samples for M. tuberculosis isolation and drug susceptibility testing. Studies with larger numbers of cases are needed to further define the performance of Xpert Ultra for the detection of M. tuberculosis in the CSF of patients with suspected TBM, including in those with and without HIV infection and in pediatric patients.

ACKNOWLEDGMENTS

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

We report no conflicts of interest.

  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    WHO. 2017. WHO Meeting Report of a Technical Expert Consultation: non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. WHO, Geneva, Switzerland.
  2. 2.↵
    1. Chakravorty S,
    2. Simmons AM,
    3. Rowneki M,
    4. Parmar H,
    5. Cao Y,
    6. Ryan J,
    7. Banada PP,
    8. Deshpande S,
    9. Shenai S,
    10. Gall A,
    11. Glass J,
    12. Krieswirth B,
    13. Schumacher SG,
    14. Nabeta P,
    15. Tukvadze N,
    16. Rodrigues C,
    17. Skrahina A,
    18. Tagliani E,
    19. Cirillo DM,
    20. Davidow A,
    21. Denkinger CM,
    22. Persing D,
    23. Kwiatkowski R,
    24. Jones M,
    25. Alland D
    . 2017. The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio 8:e00812-17. doi:10.1128/mBio.00812-17.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Dorman SE,
    2. Schumacher SG,
    3. Alland D,
    4. Nabeta P,
    5. Armstrong DT,
    6. King B,
    7. Hall SL,
    8. Chakravorty S,
    9. Cirillo DM,
    10. Tukvadze N,
    11. Bablishvili N,
    12. Stevens W,
    13. Scott L,
    14. Rodrigues C,
    15. Kazi MI,
    16. Joloba M,
    17. Nakiyingi L,
    18. Nicol MP,
    19. Ghebrekristos Y,
    20. Anyango I,
    21. Murithi W,
    22. Dietze R,
    23. Lyrio Peres R,
    24. Skrahina A,
    25. Auchynka V,
    26. Chopra KK,
    27. Hanif M,
    28. Liu X,
    29. Yuan X,
    30. Boehme CC,
    31. Ellner JJ,
    32. Denkinger CM,
    33. Dorman SE,
    34. Schumacher SG,
    35. Alland D,
    36. Nabeta P,
    37. Armstrong DT,
    38. King B,
    39. Hall SL,
    40. Chakravorty S,
    41. Cirillo DM,
    42. Tukvadze N,
    43. Bablishvili N,
    44. Stevens W,
    45. Scott L,
    46. Rodrigues C,
    47. Kazi MI,
    48. Joloba M,
    49. Nakiyingi L,
    50. Nicol MP,
    51. Ghebrekristos Y,
    52. Anyango I,
    53. Murithi W,
    54. Dietze R,
    55. Peres RL,
    56. Skrahina A,
    57. Auchynka V,
    58. Chopra KK,
    59. Hanif M,
    60. Liu X,
    61. Yuan X,
    62. Boehme CC,
    63. Ellner JJ,
    64. Denkinger CM,
    65. Manabe YC,
    66. Hom D,
    67. Aspindzelashvili R,
    68. David A,
    69. Surve U,
    70. Kamulegeya LH,
    71. Nabweyambo S,
    72. Surtie S,
    73. Hapeela N,
    74. Cain KP,
    75. Agaya J,
    76. McCarthy KD,
    77. Marques-Rodrigues P,
    78. Schmidt Castellani LG,
    79. Almeida PS,
    80. de Aguiar PPL,
    81. Solodovnikova V,
    82. Ruan X,
    83. Liang L,
    84. Zhang G,
    85. Zhu H,
    86. Xie Y
    . 2018. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis 18:76–84. doi:10.1016/S1473-3099(17)30691-6.
    OpenUrlCrossRef
  4. 4.↵
    1. Berhanu RH,
    2. David A,
    3. da Silva P,
    4. Shearer K,
    5. Sanne I,
    6. Stevens W,
    7. Scott L
    . 2018. Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for diagnosis of pulmonary tuberculosis in a high-HIV-burden setting. J Clin Microbiol 56:e00560-18. doi:10.1128/JCM.00560-18.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Nicol MP,
    2. Workman L,
    3. Prins M,
    4. Bateman L,
    5. Ghebrekristos Y,
    6. Mbhele S,
    7. Denkinger CM,
    8. Zar HJ
    . 2018. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pulmonary tuberculosis in children. Pediatr Infect Dis J 37:e261–e263. doi:10.1097/INF.0000000000001960.
    OpenUrlCrossRef
  6. 6.↵
    1. Bisognin F,
    2. Lombardi G,
    3. Lombardo D,
    4. Re MC,
    5. Dal Monte P
    . 2018. Improvement of Mycobacterium tuberculosis detection by Xpert MTB/RIF Ultra: A head-to-head comparison on Xpert-negative samples. PLoS One 13:e0201934. doi:10.1371/journal.pone.0201934.
    OpenUrlCrossRef
  7. 7.↵
    1. Opota O,
    2. Zakham F,
    3. Mazza-Stalder J,
    4. Nicod L,
    5. Greub G,
    6. Jaton K
    . 2019. Added value of Xpert MTB/RIF Ultra for diagnosis of pulmonary tuberculosis in a low-prevalence setting. J Clin Microbiol 57:e01717-18. doi:10.1128/JCM.01717-18.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Bahr NC,
    2. Nuwagira E,
    3. Evans EE,
    4. Cresswell FV,
    5. Bystrom PV,
    6. Byamukama A,
    7. Bridge SC,
    8. Bangdiwala AS,
    9. Meya DB,
    10. Denkinger CM,
    11. Muzoora C,
    12. Boulware DR
    . 2018. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infect Dis 18:68–75. doi:10.1016/S1473-3099(17)30474-7.
    OpenUrlCrossRef
  9. 9.↵
    1. Marais S,
    2. Thwaites G,
    3. Schoeman JF,
    4. Schoeman JF,
    5. Török ME,
    6. Misra UK,
    7. Prasad K,
    8. Donald PR,
    9. Wilkinson RJ,
    10. Marais BJ
    . 2010. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis 10:803–812. doi:10.1016/S1473-3099(10)70138-9.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Chin JH,
    2. Ssengooba W,
    3. Grossman S,
    4. Pellinen J,
    5. Wadda V
    . 2019. Xpert MTB/RIF Ultra: Optimal procedures for the detection of Mycobacterium tuberculosis in cerebrospinal fluid. J Clin Tuberc Other Mycobact Dis 14:16–18. doi:10.1016/j.jctube.2019.01.002.
    OpenUrlCrossRef
PreviousNext
Back to top
Download PDF
Citation Tools
Xpert MTB/RIF Ultra for Detection of Mycobacterium tuberculosis in Cerebrospinal Fluid
Jerome H. Chin, Abdu K. Musubire, Nicole Morgan, Jacob Pellinen, Scott Grossman, Jaydeep M. Bhatt, Vincent Wadda, Willy Ssengooba
Journal of Clinical Microbiology May 2019, 57 (6) e00249-19; DOI: 10.1128/JCM.00249-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Xpert MTB/RIF Ultra for Detection of Mycobacterium tuberculosis in Cerebrospinal Fluid
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Xpert MTB/RIF Ultra for Detection of Mycobacterium tuberculosis in Cerebrospinal Fluid
Jerome H. Chin, Abdu K. Musubire, Nicole Morgan, Jacob Pellinen, Scott Grossman, Jaydeep M. Bhatt, Vincent Wadda, Willy Ssengooba
Journal of Clinical Microbiology May 2019, 57 (6) e00249-19; DOI: 10.1128/JCM.00249-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • ACKNOWLEDGMENTS
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

cerebrospinal fluid
Mycobacterium tuberculosis
tuberculous meningitis
Xpert MTB/RIF

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X